Table 2. Baseline clinical characteristics of the patients (n = 24).

	Mean ± SEM or No (%)
Age (yr)	48 ± 3.0
Male, n (%)	18 (75.0)
Underlying hematologic disease, n (%) Acute myeloid leukemia Hemophagocytic lymphohistiocytosis Non-Hodgkin's lymphoma Aplastic anemia Acute lymphoblastic leukemia Myelodysplastic syndrome Multiple myeloma Chronic myelogenous leukemia Chronic lymphocytic leukemia Primary myelofibrosis	6 (25.0) 4 (16.7) 3 (12.5) 3 (12.5) 2 (8.3) 2 (8.3) 1 (4.2) 1 (4.2) 1 (4.2) 1 (4.2)
Prior treatment, n (%) Bone Marrow transplantation Use of immunosuppressant agent Systemic chemotherapy in last 30 days Alemtuzumab chemotherapy	16 (66.7) 16 (66.7) 12 (46.2) 2 (8.3)
Steroid pulse therapy in last 30 days History of preemptive CMV therapy, n (%)	3 (12.5) 4 (16.7)
Prognosis of pneumonia, n (%) Improved Aggravated Follow up periods (days)	10 (41.7) 14 (58.3) 122.0 ± 65.0
Death, n (%) Survived Before 28 days of diagnosis After 28 days of diagnosis Death due to the pneumonia, n (%)	15 (62.5) 9 (37.5) 11 (45.8) 4 (16.7) 14 (58.3)

SEM : Standard Error of the Mean

CMV : cytomegalovirus

Steroid pulse therapy : Methylprednisolone > 1 mg/kg/day